Welcome to my Heart to Heart blog designed in the Clearity Portal to provide ovarian cancer survivors with a “cozy space” where we know we will be welcomed and supported.
I’ve been an ovarian cancer survivor for 7 years. I’ve … Read more
By: Cory Bentley, PhD
Bringing new treatments to ovarian cancer patients is very challenging. There are not as many patients diagnosed with this cancer as there are with other cancer types, such as breast, lung and colorectal, so there are … Read more
By Gordon Parry, PhD & Cory Bentley, PhD
The human immune system is very powerful. Successfully harnessing the immune system to destroy tumors, cancer immunotherapy, has been a dream of many oncologists. Cancer immunotherapy has become a reality with … Read more
By: Cory Bentley, PhD
Clearity first reported on drugs inhibiting PARP (Poly-ADP ribose polymerase), an important enzyme for tumor cell proliferation and survival, in its September 2010 patient newsletter. At that time, PARP inhibitors were just entering clinical trials and
… Read moreBy: Evan Friend, MD
The concept of maintenance therapy is based on the idea that by continuing treatment, patients will delay the time to subsequent recurrence or progression of the disease. Whether or not this therapy will lead to improved … Read more
By: Cory Bentley, PhD
Most ovarian cancer patients have become familiar with CA125 blood level monitoring, but trial drug DMUC5754A from Genentech puts a new twist on this familiar blood marker of advanced ovarian cancer. CA125 (cancer antigen 125) also … Read more
By: Cory Bentley, PhD & Teresa Gallagher, PhD
A study presented at the Society of Gynecological Oncology meeting found that most women diagnosed with ovarian cancer are not receiving medical care that meets the guidelines of the National Comprehensive Cancer … Read more
By: Cory Bentley, PhD & Teresa Gallagher, PhD
Ovarian cancer is a very diverse disease on the molecular level. Different tumors have different key molecular players and potentially different Achilles’ heels. Researchers are making real progress in pinpointing key players … Read more
